Erratum to A thymine–adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus (J Gastroenterol, (2015), 50, (1069-1077), 10.1007/s00535-015-1056-1);A thymine–adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus

Journal of Gastroenterology

Volumn 50, Issue 10, 2015, Pages 1069-1077

  Hiramine, Satoshi ^a,b   Sugiyama, Masaya ^a   Furusyo, Norihiro ^b   Uto, Hirofumi ^c   Ido, Akio ^c   Tsubouchi, Hirohito ^c   Watanabe, Hisayoshi ^d   Ueno, Yoshiyuki ^d   Korenaga, Masaaki ^a   Murata, Kazumoto ^a   Masaki, Naohiko ^a   Hayashi, Jun ^b   Thomas, David L ^e   Mizokami, Masashi ^a  

^a 1 7 1 Kohnodai   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic marker; Interferon lambda 3; Microsatellite

Indexed keywords

ADENINE; INTERLEUKIN 28B; THYMINE; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; VIRUS DNA;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; DINUCLEOTIDE REPEAT LENGTH; FEMALE; GENE AND NUCLEIC ACID PARAMETERS; GENETIC VARIABILITY; HEPATITIS C VIRUS; HEREDITY; HUMAN; INFECTION; JAPANESE (PEOPLE); MALE; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; ADOLESCENT; CHRONIC HEPATITIS C; GENE FREQUENCY; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEPACIVIRUS; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; VIROLOGY; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; AGED; ALLELES; DINUCLEOTIDE REPEATS; DNA, VIRAL; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; THYMINE; YOUNG ADULT;

EID: 84943199680     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-015-1155-z     Document Type: Erratum

References (31)

1. Ray Kim W. Global epidemiology and burden of hepatitis C. Microbes Infect. 2002;4:1219–25.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–46.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.
5. Furusyo N, Kajiwara E, Takahashi K, et al. Association between the treatment length and cumulative dose of PEGylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol. 2008;23:1094–104.
6. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.
7. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.
8. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to PEGylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.
9. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.
10. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131:1887–98.
11. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.
12. Rao HY, Sun DG, Jiang D, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012;19:173–81.
13. Sugiyama M, Tanaka Y, Wakita T, et al. Genetic variation of the IL-28B promoter affecting gene expression. PLoS One. 2011;6:e26620.
14. Kishihara Y, Furusyo N, Kashiwagi K, et al. Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. J Infect Dis. 2001;184:1114–9.
15. Uto H, Stuver SO, Hayashi K, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology. 2009;50:393–9.
16. Watanabe H, Saito T, Shinzawa H, et al. Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study. J Med Virol. 2003;71:56–61.
17. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75–100.
18. Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to PEGylated alpha interferon/ribavirin therapy in Japanese patients than other single-nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49:1853–60.
19. Lyamichev V, Mast AL, Hall JG, et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol. 1999;17:292–6.
20. Lyamichev VI, Kaiser MW, Lyamicheva NE, et al. Experimental and theoretical analysis of the invasive signal amplification reaction. Biochemistry. 2000;39:9523–32.
21. Ishibashi M, Shinzawa H, Kuboki M, et al. Prevalence of inhabitants with anti-hepatitis C virus antibody in an area following an acute hepatitis C epidemic: age-and area-related features. J Epidemiol. 1996;6:1–7.
22. Uto H, Hayashi K, Kusumoto K, et al. Spontaneous elimination of hepatitis C virus RNA in individuals with persistent infection in a hyperendemic area of Japan. Hepatol Res. 2006;34:28–34.
23. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.
24. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132:105–11.
25. Raijmakers MT, Jansen PL, Steegers EA, et al. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol. 2000;33:348–51.
26. Borlak J, Thum T, Landt O, et al. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert’s syndrome) in healthy subjects. Hepatology. 2000;32:792–5.
27. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA. 1998;95:8170–4.
28. Horsfall LJ, Zeitlyn D, Tarekegn A, et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet. 2011;75:236–46.
29. Lankisch TO, Schulz C, Zwingers T, et al. Gilbert’s syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev. 2008;17:695–701.
30. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–33.
31. Tanaka Y, Nishida N, Sugiyama M, et al. lambda-Interferons and the single-nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res. 2010;40:449–60.